Peripheral Vascular Devices Market

Peripheral Vascular Devices Market Analysis

The peripheral vascular devices market size reached USD 13.92 billion in 2025 and is on course to attain USD 17.29 billion by 2030, advancing at a 4.43% CAGR. Stable growth rests on higher procedure volumes fueled by global population aging, rising diabetes prevalence, and broader recognition of peripheral artery disease (PAD) as a cardiovascular risk equivalent. Regulatory friction under the European Union Medical Device Regulation (EU-MDR) slows new product approvals, but technology innovation—especially artificial intelligence (AI)–guided imaging and robotic catheter systems—continues to improve clinical efficiency. Consolidation among large manufacturers accelerates access to differentiated technologies such as intravascular lithotripsy, while outpatient migration of revascularization procedures supports cost-effective care delivery. Against this backdrop, the peripheral vascular devices market continues to favor products that demonstrate durable clinical outcomes and economic value to payers and providers.

Global Peripheral Vascular Devices Market Trends and Insights

Rising Prevalence of PAD & CVD

PAD affects 113 million people worldwide and has grown 23.5% since 2010, directly expanding the peripheral vascular devices market. Diabetes multiplies PAD incidence 2–4 times, pushing intervention demand into younger cohorts. Disability-adjusted life-years attributable to PAD have climbed 40% since 2010, pressuring health systems to prioritize early diagnosis and endovascular therapy. Clinical guidelines now align PAD risk with coronary artery disease, prompting insurers to maintain favorable reimbursement for revascularization procedures. Together, these epidemiological trends underpin enduring device demand across mature and emerging regions.

Ageing Population & Diabetes Comorbidity

Adults aged ≥ 65 years show PAD prevalence above 20% versus 4.3% in younger adults. Within this cohort, diabetes occurs in 26.8% of patients, escalating lesion calcification and necessitating premium atherectomy and lithotripsy devices. Aging also correlates with multi-vessel disease, spurring multi-device use per procedure. Payers increasingly endorse early intervention to avoid limb loss and downstream healthcare costs, sustaining procedural volume even when macroeconomic pressures constrain hospital budgets.

Adoption of Minimally-Invasive Endovascular Procedures

Endovascular techniques accounted for more than 80% of peripheral revascularizations in 2024 and continue to penetrate surgical bypass indications thanks to shorter recovery times and equivalent limb salvage outcomes. IQVIA projects 25% outpatient vascular procedure growth through 2028, aligning with payer incentives for site-of-service cost reduction. Drug-coated balloons deliver 92% freedom from clinically driven target-lesion revascularization at 12 months, reinforcing physician confidence. As device profiles broaden to smaller-diameter vessels, minimally invasive approaches attract previously ineligible patients, extending the peripheral vascular devices market.

Rapid Advances in Drug-Coated Balloons & Stents

Boston Scientific’s AGENT drug-coated balloon gained FDA clearance in March 2024 after demonstrating 82% primary patency at 12 months. Sirolimus-coated balloons with Breakthrough Device Designation promise lower restenosis risk in arteriovenous fistula indications. Evidence from real-world registries aligns with trial data, prompting payers to reimburse at premium price points. The result is a technology shift away from plain angioplasty, reinforcing revenue growth even as unit prices face pressure.

Stringent Regulatory & EU-MDR Delays

EU-MDR lifted recertification requirements for legacy devices, leaving 85% of prior CE-marked products uncertified as of April 2024. Notified-body bottlenecks stretch review cycles to 18-36 months, delaying European launches and cascading into countries that rely on EU regulatory decisions. Compliance costs can exceed USD 2 million per product family, straining mid-size innovators and narrowing product lines in smaller indications.

Device Recalls & Safety Concerns

Peripheral device recalls rose 23% in 2024, dominated by manufacturing defects and long-term device-related events that triggered mandatory 483 warnings. Litigation over inferior vena cava filters resulted in settlements exceeding USD 2.5 billion, prompting physicians to prefer retrievable or short-dwell alternatives. Safety alerts extend beyond affected devices, generating caution for newer entrants until long-term data are available.

Segment Analysis

By Product Type: Stents Sustain Leadership While Atherectomy Drives Incremental Growth

Peripheral vascular stents dominated 78.64% of the peripheral vascular devices market in 2024 owing to proven durability across iliac, femoropopliteal, and infrapopliteal segments. Although stent adoption remains robust, atherectomy devices are projected to register a 16.67% CAGR to 2030 as calcified lesion prevalence rises within diabetic populations. The Golazo Peripheral Atherectomy System cleared by the Centers for Medicare & Medicaid Services exemplifies regulatory support for mechanical plaque removal innovations.

Atherectomy’s rapid growth does not eclipse established segments like percutaneous transluminal angioplasty (PTA) balloons, which retain procedural versatility and price advantages. Thrombectomy devices, validated by 99.1% limb-salvage rates in the THRIVE analysis, gain share in acute limb ischemia interventions. Vascular closure devices achieve 7.9% CAGR as same-day discharge protocols spread, while aortic stent grafts expand through adjunct technologies such as endo-anchors that accommodate hostile neck anatomies.

By End User: Ambulatory Surgical Centers Accelerate Yet Hospitals Retain Scale Advantage

Hospitals generated 60.06% of 2024 revenue, supported by intensive-care capability and multispecialty coordination. However, ambulatory surgical centers (ASCs) are forecast to grow at 17.45% CAGR, reflecting payer preference for lower cost sites and physician ownership interest. CMS approvals for outpatient use of drug-coated balloons and atherectomy systems reinforce this shift, positioning ASCs to capture an additional 12% volume share by 2030.

Specialty vascular clinics—often extensions of office-based labs—supplement ASC growth by focusing exclusively on limb salvage programs. Hospitals are responding through joint-venture outpatient centers and by integrating AI-enabled imaging suites to retain complex cases. Nonetheless, outpatient migration is irreversible, forcing manufacturers to refine distribution models that support small-batch, just-in-time inventory for dispersed facilities.

Geography Analysis

North America accounted for 42.45% of 2024 revenue on the strength of mature reimbursement systems and early adoption of AI-guided imaging that achieves 82% procedural precision. The United States drives growth through nearly 700 office-based labs expanding at 7.5% annually, while Canada leverages universal coverage to ensure broad access to endovascular therapy. The peripheral vascular devices market size in North America is expected to advance from USD 5.91 billion in 2025 to USD 6.99 billion by 2030.

Asia-Pacific is the fastest growing region at a 17.94% CAGR, fueled by middle-class expansion, capacity upgrades, and standards such as YY/T 1898-2024 that clarify hydrophilic-coating performance benchmarks. China’s volume-based procurement policy compresses unit prices yet balloons aggregate demand, allowing international and local players to scale manufacturing footprints. India’s Materiovigilance Programme increases post-market transparency, driving hospitals toward devices with proven safety data. Japan and South Korea remain early adopters of robotic catheter systems, anchoring premium-segment sales.

Europe sustains meaningful demand despite EU-MDR delays that slowed new-product turnover. Germany and France lead utilization, emphasizing evidence-based purchasing decisions that reward long-term outcome data. The United Kingdom’s post-Brexit regulatory pathway introduces parallel approval costs but retains high procedure volumes. South America and the Middle East & Africa represent emerging opportunities; Brazil and Saudi Arabia spearhead catheter-laboratory expansion, although reimbursement ceilings temper rapid uptake of premium devices. Overall, the peripheral vascular devices market continues to globalize, prompting manufacturers to regionalize supply chains and tailor portfolios to local economic realities.

Competitive Landscape

The peripheral vascular devices market demonstrates moderate consolidation layered over vigorous mid-tier competition. Johnson & Johnson closed its USD 13.1 billion acquisition of Shockwave Medical in August 2024, adding intravascular lithotripsy that targets calcified lesions refractory to balloon angioplasty. Boston Scientific followed with a USD 1.16 billion takeover of Silk Road Medical, securing the TCAR platform for stroke-prevention carotid interventions. Abbott deepened its thrombectomy presence by buying Walk Vascular and the JETi AIO aspiration system.

Large strategics harness these deals to assemble end-to-end vascular portfolios that align with value-based reimbursement. Smaller innovators such as Amplitude Vascular Systems progress through Investigational Device Exemption studies for Pulse Intravascular Lithotripsy, challenging incumbents in the calcified-lesion niche. AI-enabled imaging start-ups partner with stent manufacturers to embed software algorithms into procedural workflows, offering holistic solutions that improve cath-lab productivity.

Competition increasingly revolves around generating real-world evidence that links device use to reduced reintervention rates and total-episode costs. Companies invest in post-market registries compliant with EU-MDR surveillance mandates, turning regulatory burden into data-driven competitive advantage. Pricing remains under pressure from hospital procurement groups and Asia-Pacific tender systems, yet differentiated technologies that shorten procedure time or eliminate staged interventions command premium margins and insulate manufacturers from commoditization.